Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 305.00
Bid: 304.00
Ask: 306.00
Change: 4.00 (1.33%)
Spread: 2.00 (0.658%)
Open: 301.50
High: 307.00
Low: 301.50
Prev. Close: 301.00
SYNT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Pricing of senior notes

12 Apr 2024 07:00

RNS Number : 3607K
Synthomer PLC
12 April 2024
 

April 12, 2024

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO

 

SYNTHOMER PLCPRICING OF SENIOR NOTES

Synthomer plc ("Synthomer") today announces that it has priced its offering (the "Offering") of €350 million in aggregate principal amount of senior notes due 2029 (the "Notes") at a coupon of 7⅜%.

The Notes will be unconditionally guaranteed by certain of Synthomer's subsidiaries. Synthomer intends to use the proceeds from this Offering, together with cash on balance sheet, to (i) repurchase or redeem certain of its existing 3⅞% senior notes due 2025 (the "Existing Notes") and (ii) pay certain costs, expenses and fees relating to the Offering.

The Offering is expected to close on or about April 18, 2024, subject to customary conditions precedent for similar transactions.

Lily Liu, Synthomer plc Chief Financial Officer, commented: "We are very pleased with the substantial support for this transaction, which represents another major milestone in improving our financial platform, and puts Synthomer in a stronger position to deliver our strategy."

 

 

Cautionary Statement

The Offering is being made by means of an offering memorandum. This announcement does not constitute an offer to sell or the solicitation of an offer to buy the Notes or any other security and shall not constitute an offer, solicitation or sale in the United States or in any jurisdiction in which, or to any persons to whom, such offering, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any jurisdiction.

The Notes have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold within the United States, or to, or for the account or benefit of, U.S. persons, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state or local securities laws. Accordingly, the Notes are being offered and sold in the United States only to qualified institutional buyers in accordance with Rule 144A under the Securities Act and to non-U.S. persons outside the United States in accordance with Regulation S under the Securities Act.

Promotion of the Notes in the United Kingdom is restricted by the Financial Services and Markets Act 2000 (the "FSMA"), and accordingly, the Notes are not being promoted to the general public in the United Kingdom. This announcement is only addressed to and directed at persons who (i) are outside the United Kingdom, (ii) have professional experience in matters relating to investments (being investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Financial Promotion Order")), (iii) fall within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations, etc.") of the Financial Promotion Order, or (iv) to the extent that doing so does not prejudice the lawful distribution of the announcement to the foregoing, are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the FSMA) in connection with the issue or sale of any Notes may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "relevant persons"). The Notes will only be available to relevant persons and this announcement must not be acted on or relied on by anyone who is not a relevant person. No key information document required by Regulation (EU) No 1286/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 (the "EUWA") (the "UK PRIIPs Regulation") for offering or selling the Notes or otherwise making them available to retail investors in the UK has been prepared and, therefore, offering or selling the Notes or otherwise making them available to any retail investor in the UK may be unlawful under the UK PRIIPs Regulation. Any offer of the Notes in the UK will be made pursuant to an exemption under Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the EUWA from a requirement to publish a prospectus for offers of securities.

This announcement does not constitute and shall not, in any circumstances, constitute a public offering nor an invitation to the public in connection with any offer within the meaning of the Regulation (EU) 2017/1129 (as amended), and any relevant implementing measure in the relevant Member State of the European Economic Area (the "Prospectus Regulation"). The offer and sale of the Notes will be made pursuant to an exemption under the Prospectus Directive, as implemented in Member States of the European Economic Area, from the requirement to produce a prospectus for offers of securities.

Manufacturer target market (MIFID II product governance) is eligible counterparties and professional clients only (all distribution channels). No PRIIPs key information document (KID) has been prepared as not available to retail investors in EEA.

This press release may include "forward looking statements" within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. These forward looking statements can be identified by the use of forward looking terminology, including the terms "believes," "estimates," "anticipates," "expects," "intends," "may," "will" or "should" or, in each case, their negative, or other variations or comparable terminology. These forward looking statements include all matters that are not historical facts and include statements regarding Synthomer or its affiliates' intentions, beliefs or current expectations concerning, among other things, the Offering.

By their nature, forward looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Readers are cautioned that forward looking statements are not guarantees of future performance and that Synthomer and its affiliates' actual results of operations, financial condition and liquidity, and the development of the industry in which they operate may differ materially from those made in or suggested by the forward looking statements contained in this press release. In addition, even if Synthomer or its affiliates' results of operations, financial condition and liquidity, and the development of the industry in which the Synthomer operates are consistent with the forward looking statements contained in this press release, those results or developments may not be indicative of results or developments in subsequent periods. Given these risks and uncertainties, you should not rely on forward looking statements as a prediction of actual results.

Statements of intent in this press release shall not constitute a notice of redemption under the indenture governing Synthomer's 3⅞% senior notes due 2025. Any such notice, if made, will only be made in accordance with the provisions of the relevant indenture.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IODDBGDSUBBDGSB
Date   Source Headline
7th Apr 201110:01 amRNSHolding(s) in Company
7th Apr 20119:15 amRNSAnnual Financial Report
31st Mar 20113:48 pmRNSAcquisition
30th Mar 20114:38 pmRNSHolding(s) in Company
18th Mar 20114:28 pmRNSHolding(s) in Company
15th Mar 20111:42 pmRNSHolding(s) in Company
15th Mar 201110:15 amRNSHolding(s) in Company
14th Mar 201111:22 amRNSHolding(s) in Company
14th Mar 201111:20 amRNSEBT Share Purchase
9th Mar 20117:00 amRNSFinal Results
8th Mar 201111:58 amRNSHolding(s) in Company
8th Mar 20119:17 amRNSDirector Declaration
2nd Mar 20114:47 pmRNSHolding(s) in Company
2nd Mar 201110:27 amRNSAcquisition
15th Feb 20119:40 amRNSAcquisition of Polymer Latex
31st Jan 201112:16 pmRNSDirector/PDMR Shareholding
31st Jan 201111:50 amRNSTotal Voting Rights
20th Jan 201111:26 amRNSHolding(s) in Company
20th Jan 201111:24 amRNSHolding(s) in Company
18th Jan 20114:19 pmRNSHolding(s) in Company
18th Jan 20119:58 amRNSResult of Equity Issue
17th Jan 20115:28 pmRNSResult of Equity Issue
14th Jan 20111:21 pmRNSHolding(s) in Company
13th Jan 20114:33 pmPRNCorrection : Disclosure of Short Position
5th Jan 201112:15 pmRNSDirector/PDMR Shareholding
4th Jan 20111:03 pmRNSHolding(s) in Company
30th Dec 201011:31 amRNSResult of EGM
16th Dec 20105:15 pmRNSHolding(s) in Company
16th Dec 20105:13 pmRNSHolding(s) in Company
16th Dec 20105:05 pmRNSHolding(s) in Company
13th Dec 20105:12 pmRNSPublication of Prospectus
13th Dec 20107:00 amRNSAcquisition and Rights Issue
23rd Nov 201011:42 amRNSHolding(s) in Company
11th Nov 20107:00 amRNSInterim Management Statement
16th Sep 20109:37 amRNSHolding(s) in Company
14th Sep 201010:31 amRNSHolding(s) in Company
26th Aug 20105:42 pmRNSAppointment of Senior Independent Director
26th Aug 20107:00 amRNSHalf Yearly Report
28th Jun 20101:18 pmRNSDirectorate Change
24th Jun 20107:00 amRNSPre-close Trading Update
2nd Jun 20108:54 amRNSCompletion of disposal
6th May 201012:32 pmRNSResult of AGM
6th May 201011:00 amRNSInterim Management Statement
30th Apr 201012:40 pmRNSAnnual Information Update
8th Apr 20107:00 amRNSAnnual Financial Report
12th Mar 20107:00 amRNSDisposal
11th Mar 201010:32 amRNSDirector/PDMR Shareholding
11th Mar 201010:31 amRNSDirector/PDMR Shareholding
10th Mar 20107:00 amRNSFinal Results
11th Feb 201012:32 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.